Cytokinetics

AI Score

XX

Unlock

37.90
-2.29 (-5.70%)
At close: Apr 01, 2025, 3:06 PM

Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.

The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.

Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc.

The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics
Cytokinetics logo
Country United States
IPO Date Apr 30, 2004
Industry Biotechnology
Sector Healthcare
Employees 498
CEO Robert I. Blum

Contact Details

Address:
350 Oyster Point Boulevard
South San Francisco, California
United States
Website https://www.cytokinetics.com

Stock Details

Ticker Symbol CYTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001061983
CUSIP Number 23282W605
ISIN Number US23282W6057
Employer ID 94-3291317
SIC Code 2834

Key Executives

Name Position
Robert I. Blum Chief Executive Officer, President & Director
Sung H. Lee Executive Vice President, Principal Financial & Accounting Officer and Chief Financial Officer
Andrew M. Callos Executive Vice President & Chief Commercial Officer
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Executive Vice President of Research & Development
Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board
Holly Laughlin Vice President of Accounting & Corporate Controller
Jeff Lotz Vice President of Sales & Operations
Kari K. Loeser J.D. Vice President & Chief Compliance Officer
Matt Yang Vice President of Corporate Finance and Financial Planning & Analysis
Steven M. Cook J.D. Senior Vice President of Global Supply Chain Operations & Technical Operations

Latest SEC Filings

Date Type Title
Mar 31, 2025 4 Filing
Mar 31, 2025 PRE 14A Filing
Mar 19, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 18, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 17, 2025 4 Filing